http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021157916-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6729b065750246c23b711a95c72ad775
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-308
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-1868
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-12
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-18
filingDate 2021-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7586b2b19d50fe65216bcd2bedad370
publicationDate 2021-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2021157916-A1
titleOfInvention Unsaturated fatty acid-conjugated cp2c-targeting peptide-based anticancer agent
abstract The present invention relates to an unsaturated fatty acid-conjugated CP2c-targeting peptide-based anticancer agent. In the present invention, when conjugated with an unsaturated fatty acid, ACP52C, which is a leading CP2c-targeting peptide substance exhibiting an effect as a general-purpose anticancer agent, was found to improve in-vivo stability without affecting the anticancer effect. It was also observed to have cancer cell-specific anticancer efficacy in various cancer cells and normal cells.
priorityDate 2020-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160117198-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180024581-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9412530-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226521505
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5789
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409524
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4122
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10112441
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399464
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226400382
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409525
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1134
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID216239

Total number of triples: 43.